Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.10
NYSE:DGX's Cash-to-Debt is ranked lower than
93% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. NYSE:DGX: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:DGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: N/A
Current: 0.1
Equity-to-Asset 0.46
NYSE:DGX's Equity-to-Asset is ranked lower than
67% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NYSE:DGX: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:DGX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.44 Max: 0.62
Current: 0.46
0.3
0.62
Interest Coverage 8.96
NYSE:DGX's Interest Coverage is ranked lower than
70% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. NYSE:DGX: 8.96 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:DGX' s Interest Coverage Range Over the Past 10 Years
Min: 5.74  Med: 7.97 Max: 9.27
Current: 8.96
5.74
9.27
Piotroski F-Score: 8
Altman Z-Score: 3.79
Beneish M-Score: -2.64
WACC vs ROIC
6.95%
9.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 17.20
NYSE:DGX's Operating Margin % is ranked higher than
86% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. NYSE:DGX: 17.20 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:DGX' s Operating Margin % Range Over the Past 10 Years
Min: 13.22  Med: 16.93 Max: 20.64
Current: 17.2
13.22
20.64
Net Margin % 9.35
NYSE:DGX's Net Margin % is ranked higher than
76% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. NYSE:DGX: 9.35 )
Ranked among companies with meaningful Net Margin % only.
NYSE:DGX' s Net Margin % Range Over the Past 10 Years
Min: 5.07  Med: 8.3 Max: 11.88
Current: 9.35
5.07
11.88
ROE % 15.18
NYSE:DGX's ROE % is ranked higher than
76% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. NYSE:DGX: 15.18 )
Ranked among companies with meaningful ROE % only.
NYSE:DGX' s ROE % Range Over the Past 10 Years
Min: 10.72  Med: 14.94 Max: 20.93
Current: 15.18
10.72
20.93
ROA % 6.98
NYSE:DGX's ROA % is ranked higher than
73% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NYSE:DGX: 6.98 )
Ranked among companies with meaningful ROA % only.
NYSE:DGX' s ROA % Range Over the Past 10 Years
Min: 4.78  Med: 6.64 Max: 9.31
Current: 6.98
4.78
9.31
ROC (Joel Greenblatt) % 112.07
NYSE:DGX's ROC (Joel Greenblatt) % is ranked higher than
92% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NYSE:DGX: 112.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:DGX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 88  Med: 116.04 Max: 143.99
Current: 112.07
88
143.99
3-Year Revenue Growth Rate 4.30
NYSE:DGX's 3-Year Revenue Growth Rate is ranked lower than
52% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NYSE:DGX: 4.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:DGX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 3.5  Med: 7.9 Max: 15.4
Current: 4.3
3.5
15.4
3-Year EBITDA Growth Rate -2.40
NYSE:DGX's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. NYSE:DGX: -2.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:DGX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.4  Med: 9.3 Max: 44.4
Current: -2.4
-2.4
44.4
3-Year EPS without NRI Growth Rate -5.30
NYSE:DGX's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. NYSE:DGX: -5.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:DGX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.45 Max: 61.5
Current: -5.3
0
61.5
GuruFocus has detected 6 Warning Signs with Quest Diagnostics Inc $NYSE:DGX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:DGX's 30-Y Financials

Financials (Next Earnings Date: 2017-07-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

DGX Guru Trades in Q2 2016

Pioneer Investments 184,754 sh (+50.01%)
Jeff Auxier 69,955 sh (unchged)
John Hussman 2,000 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Murray Stahl 7,300 sh (-0.68%)
Chris Davis 3,279,494 sh (-1.06%)
David Dreman 13,474 sh (-4.16%)
Scott Black 30,000 sh (-4.30%)
Charles Brandes 146,794 sh (-9.77%)
Paul Tudor Jones 6,000 sh (-11.58%)
Joel Greenblatt 177,438 sh (-28.80%)
John Rogers 454,535 sh (-39.16%)
» More
Q3 2016

DGX Guru Trades in Q3 2016

Lee Ainslie 37,510 sh (New)
John Hussman 76,500 sh (+3725.00%)
Joel Greenblatt 308,220 sh (+73.71%)
Paul Tudor Jones 6,000 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Pioneer Investments Sold Out
Jeff Auxier 69,530 sh (-0.61%)
Murray Stahl 7,250 sh (-0.68%)
Charles Brandes 141,534 sh (-3.58%)
David Dreman 12,702 sh (-5.73%)
Scott Black 28,269 sh (-5.77%)
John Rogers 404,984 sh (-10.90%)
Chris Davis 239,896 sh (-92.68%)
» More
Q4 2016

DGX Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 7,625 sh (New)
Jim Simons 58,900 sh (New)
John Hussman 100,000 sh (+30.72%)
Charles Brandes 141,713 sh (+0.13%)
Bernard Horn 61,733 sh (unchged)
Lee Ainslie Sold Out
Paul Tudor Jones Sold Out
Murray Stahl 6,900 sh (-4.83%)
David Dreman 11,851 sh (-6.70%)
John Rogers 371,880 sh (-8.17%)
Chris Davis 203,698 sh (-15.09%)
Jeff Auxier 53,995 sh (-22.34%)
Joel Greenblatt 234,372 sh (-23.96%)
Scott Black 21,059 sh (-25.50%)
» More
Q1 2017

DGX Guru Trades in Q1 2017

Barrow, Hanley, Mewhinney & Strauss 763 sh (New)
Jeremy Grantham 2,700 sh (New)
Caxton Associates 6,700 sh (New)
Jim Simons 503,700 sh (+755.18%)
Manning & Napier Advisors, Inc 7,625 sh (unchged)
Scott Black Sold Out
Murray Stahl 6,800 sh (-1.45%)
David Dreman 11,370 sh (-4.06%)
Jeff Auxier 45,845 sh (-15.09%)
Joel Greenblatt 180,978 sh (-22.78%)
John Hussman 75,000 sh (-25.00%)
Chris Davis 129,419 sh (-36.47%)
John Rogers 220,617 sh (-40.68%)
Charles Brandes 78,932 sh (-44.30%)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:IDXX, NYSE:LH, OTCPK:SSMXY, NYSE:Q, NYSE:A, OTCPK:ERFSF, OTCPK:BMXMF, NAS:QGEN, NYSE:PKI, OTCPK:SUVPF, NYSE:BIO.B, NAS:INCR, NAS:DXCM, NAS:ICLR, OTCPK:CZMWF, NAS:PRAH, NYSE:CRL, NAS:VWR, NAS:BRKR, NYSE:ALR » details
Traded in other countries:QDI.Germany,
Headquarter Location:USA
Quest Diagnostics Inc is the provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates about 90% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing at its national network of 2,000 patient service centers. The firm also runs a diagnostic solutions segment which provides clinical trials testing, risk assessment services, and information technology solutions.

Top Ranked Articles about Quest Diagnostics Inc

7 Best Stocks For Value Investors This Week - 7/30/16 These companies were found and reviewed by ModernGraham
I evaluated 20 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. I also put each company through the ModernGraham valuation model based on Benjamin Graham's value investing formulas in order to determine an intrinsic value for each. Out of those 20 companies, only seven were found to be undervalued or fairly valued and suitable for either Defensive or Enterprising Investors. Read more...

Ratios

vs
industry
vs
history
PE Ratio 21.77
DGX's PE Ratio is ranked higher than
69% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. DGX: 21.77 )
Ranked among companies with meaningful PE Ratio only.
DGX' s PE Ratio Range Over the Past 10 Years
Min: 9.09  Med: 17.26 Max: 31.26
Current: 21.77
9.09
31.26
Forward PE Ratio 19.65
DGX's Forward PE Ratio is ranked higher than
67% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. DGX: 19.65 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.77
DGX's PE Ratio without NRI is ranked higher than
68% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. DGX: 21.77 )
Ranked among companies with meaningful PE Ratio without NRI only.
DGX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.48  Med: 15.54 Max: 22.3
Current: 21.77
9.48
22.3
Price-to-Owner-Earnings 27.02
DGX's Price-to-Owner-Earnings is ranked higher than
50% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. DGX: 27.02 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DGX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.27  Med: 26.41 Max: 129.96
Current: 27.02
12.27
129.96
PB Ratio 3.20
DGX's PB Ratio is ranked higher than
60% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. DGX: 3.20 )
Ranked among companies with meaningful PB Ratio only.
DGX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.46 Max: 4.31
Current: 3.2
1.85
4.31
PS Ratio 2.02
DGX's PS Ratio is ranked higher than
74% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. DGX: 2.02 )
Ranked among companies with meaningful PS Ratio only.
DGX' s PS Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.35 Max: 2.17
Current: 2.02
1.03
2.17
Price-to-Free-Cash-Flow 18.50
DGX's Price-to-Free-Cash-Flow is ranked higher than
66% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. DGX: 18.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DGX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.23  Med: 13.88 Max: 21.58
Current: 18.5
8.23
21.58
Price-to-Operating-Cash-Flow 13.69
DGX's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. DGX: 13.69 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DGX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 10.91 Max: 14.43
Current: 13.69
6.98
14.43
EV-to-EBIT 13.44
DGX's EV-to-EBIT is ranked higher than
86% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. DGX: 13.44 )
Ranked among companies with meaningful EV-to-EBIT only.
DGX' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.2  Med: 10.4 Max: 15.2
Current: 13.44
7.2
15.2
EV-to-EBITDA 11.35
DGX's EV-to-EBITDA is ranked higher than
77% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. DGX: 11.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
DGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 8.6 Max: 11.8
Current: 11.35
6.1
11.8
PEG Ratio 4.19
DGX's PEG Ratio is ranked lower than
67% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. DGX: 4.19 )
Ranked among companies with meaningful PEG Ratio only.
DGX' s PEG Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.94 Max: 5.88
Current: 4.19
0.81
5.88
Shiller PE Ratio 26.32
DGX's Shiller PE Ratio is ranked higher than
83% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. DGX: 26.32 )
Ranked among companies with meaningful Shiller PE Ratio only.
DGX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.47  Med: 20.05 Max: 38.66
Current: 26.32
14.47
38.66
Current Ratio 1.58
DGX's Current Ratio is ranked lower than
73% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. DGX: 1.58 )
Ranked among companies with meaningful Current Ratio only.
DGX' s Current Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.28 Max: 2.15
Current: 1.58
0.74
2.15
Quick Ratio 1.50
DGX's Quick Ratio is ranked lower than
69% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. DGX: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
DGX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.2 Max: 2.03
Current: 1.5
0.7
2.03
Days Inventory 6.34
DGX's Days Inventory is ranked higher than
94% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. DGX: 6.34 )
Ranked among companies with meaningful Days Inventory only.
DGX' s Days Inventory Range Over the Past 10 Years
Min: 6.56  Med: 7.69 Max: 8.46
Current: 6.34
6.56
8.46
Days Sales Outstanding 46.40
DGX's Days Sales Outstanding is ranked higher than
74% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. DGX: 46.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
DGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.51  Med: 43.71 Max: 48.01
Current: 46.4
40.51
48.01
Days Payable 20.54
DGX's Days Payable is ranked lower than
82% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. DGX: 20.54 )
Ranked among companies with meaningful Days Payable only.
DGX' s Days Payable Range Over the Past 10 Years
Min: 16.4  Med: 18.43 Max: 21.87
Current: 20.54
16.4
21.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.57
DGX's Dividend Yield % is ranked higher than
74% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. DGX: 1.57 )
Ranked among companies with meaningful Dividend Yield % only.
DGX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.6  Med: 0.87 Max: 2.46
Current: 1.57
0.6
2.46
Dividend Payout Ratio 0.34
DGX's Dividend Payout Ratio is ranked lower than
68% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.24 vs. DGX: 0.34 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DGX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.17 Max: 0.45
Current: 0.34
0.1
0.45
3-Year Dividend Growth Rate 10.60
DGX's 3-Year Dividend Growth Rate is ranked lower than
66% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.60 vs. DGX: 10.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DGX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.15 Max: 55.4
Current: 10.6
0
55.4
Forward Dividend Yield % 1.67
DGX's Forward Dividend Yield % is ranked higher than
70% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. DGX: 1.67 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.63
DGX's 5-Year Yield-on-Cost % is ranked higher than
94% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. DGX: 6.63 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DGX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.53  Med: 3.68 Max: 10.39
Current: 6.63
2.53
10.39
3-Year Average Share Buyback Ratio 1.60
DGX's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. DGX: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.9  Med: 1.5 Max: 7
Current: 1.6
-16.9
7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.47
DGX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. DGX: 1.47 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DGX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.65  Med: 0.9 Max: 3.77
Current: 1.47
0.65
3.77
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.03
DGX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
71% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. DGX: 2.03 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.50
DGX's Price-to-Median-PS-Value is ranked lower than
73% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. DGX: 1.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DGX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.02 Max: 1.65
Current: 1.5
0.24
1.65
Earnings Yield (Greenblatt) % 7.44
DGX's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. DGX: 7.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DGX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.6  Med: 9.6 Max: 13.8
Current: 7.44
6.6
13.8
Forward Rate of Return (Yacktman) % 7.91
DGX's Forward Rate of Return (Yacktman) % is ranked higher than
54% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. DGX: 7.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DGX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.9  Med: 14.5 Max: 25.1
Current: 7.91
7.9
25.1

More Statistics

Revenue (TTM) (Mil) $7,551
EPS (TTM) $ 4.96
Beta0.97
Short Percentage of Float4.93%
52-Week Range $75.20 - 108.61
Shares Outstanding (Mil)136.83

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 7,675 7,830 8,040
EPS ($) 5.49 5.82 6.28
EPS without NRI ($) 5.49 5.82 6.28
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.88%
Dividends per Share ($) 1.72 1.89 2.15
» More Articles for DGX

Headlines

Articles On GuruFocus.com
Quest Diagnostics Declares Quarterly Cash Dividend May 16 2017 
Increases in Illicit Drugs, Including Cocaine, Drive Workforce Drug Positivity to Highest Rate in 12 May 16 2017 
Quest Diagnostics To Speak At The UBS Global Healthcare Conference May 12 2017 
Quest Diagnostics To Speak At The Deutsche Bank 42nd Annual Health Care Conference May 02 2017 
Quest Diagnostics and PeaceHealth Complete Transaction to Increase Access to Innovative, High-value May 01 2017 
Quest Diagnostics CIO Lidia Fonseca Wins 2017 Forbes CIO Innovation Award May 01 2017 
Data Diagnostics Wins Gold at the 30th Annual Edison Awards Apr 24 2017 
Quest Diagnostics 50th Anniversary: Celebrating a Half Century of Life-Changing Results Apr 24 2017 
Quest Diagnostics To Release First Quarter 2017 Financial Results On April 20 Apr 07 2017 
Quest Diagnostics Presents Supplier Excellence Awards to Five Partners Apr 06 2017 

More From Other Websites
Quest Diagnostics Pushes Beyond Lab Tests With Treatment Prediction May 26 2017
Quest Diagnostics Hits a 52-Week High on Solid Prospects May 26 2017
3 Top Dividend Stocks in Gene Sequencing May 24 2017
Quest Diagnostics (DGX) Up 1.8% Since Earnings Report: Can It Continue? May 23 2017
Quest Diagnostics Poised on Solid Q1 Results Despite Woes May 22 2017
These states have the most workers using illegal drugs May 17 2017
[$$] More American Workers Are Testing Positive for Drugs May 16 2017
Quest Diagnostics Declares Quarterly Cash Dividend May 16 2017
Increases in Illicit Drugs, Including Cocaine, Drive Workforce Drug Positivity to Highest Rate in 12... May 16 2017
Quest Diagnostics To Speak At The UBS Global Healthcare Conference May 12 2017
CSAIL 2016-C6 Commercial Mortgage Trust -- Moody's Affirms Eight Classes of CSAIL 2016-C6 May 04 2017
Quest Diagnostics To Speak At The Deutsche Bank 42nd Annual Health Care Conference May 02 2017
Quest Diagnostics and PeaceHealth Complete Transaction to Increase Access to Innovative, High-value... May 01 2017
Quest Diagnostics CIO Lidia Fonseca Wins 2017 Forbes CIO Innovation Award May 01 2017
Quest Diagnostics CIO Harnesses Insights And Technology For Better Healthcare Results May 01 2017
J.P. Morgan Chase Commercial Mortgage Securities Corp. 2004-C3 -- Moody's Affirms Four Classes of... Apr 27 2017
Chipotle Downgraded; McDonald's Gets Price Hikes; Snap Started At Hold Apr 26 2017
Quest Diagnostics’ Multi-Pronged Strategy to Accelerate Growth Apr 26 2017
Quest Diagnostics Is Targeting 3 Focus Areas to Accelerate Growth Apr 26 2017
Quest Diagnostics Is Making Steady Progress in 5-Point Strategy Apr 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)